Collaboration to focus on enabling clinicians to open clinical trials at the point of care.
Flatiron Health announced that it will be partnering with Penn Medicine to bring its Flatiron Assist to Penn’s Abramson Cancer Center (ACC). The project aims to further enable clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
“At Flatiron, we are committed to elevating clinical care and unlocking the power of patient data, so every person’s experience can inform and improve outcomes for future patients. Partnering with Penn Medicine’s Abramson Cancer Center, a market-leading cancer care provider and a pioneer of digital innovation in healthcare, enables us to use data for good and reimagine the infrastructure of cancer care,” said Julia Morton, SVP, GM, Flatiron HC. “We are looking forward to working together to accelerate the delivery of more standardized, efficient, and effective cancer care across the entire health system.”
Reference: Flatiron Health Launches New Strategic Collaboration to Advance Health Insights and Equity of Cancer Care. BusiessWire. October 23, 2023. Accessed October 23, 2023. https://www.businesswire.com/news/home/20231023565932/en/Flatiron-Health-Launches-New-Strategic-Collaboration-to-Advance-Health-Insights-and-Equity-of-Cancer-Care
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.